Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-921 in chemotherapy-naive metastatic castration-resistant prostate cancer
NL-OMON52582Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Pembrolizumab + docetaxel + prednisone with Placebo + docetaxel + prednisone (2 arms). Primary endpoints: overall survival and radiographic progression-free survival. Started Sep 2019; status: active, not recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52582.